Illumina, Inc. (NASDAQ:ILMN) CFO Sam Samad Sells 892 Shares

Illumina, Inc. (NASDAQ:ILMN) CFO Sam Samad sold 892 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $320.00, for a total value of $285,440.00. Following the completion of the sale, the chief financial officer now owns 3,461 shares in the company, valued at $1,107,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ ILMN opened at $319.68 on Friday. Illumina, Inc. has a fifty-two week low of $263.30 and a fifty-two week high of $380.76. The firm’s 50-day simple moving average is $307.46 and its 200 day simple moving average is $310.22. The company has a quick ratio of 6.15, a current ratio of 6.82 and a debt-to-equity ratio of 0.41. The stock has a market cap of $47.15 billion, a P/E ratio of 55.89, a P/E/G ratio of 2.37 and a beta of 1.06.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.53. The firm had revenue of $907.00 million during the quarter, compared to analyst estimates of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. Illumina’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.52 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 6.45 earnings per share for the current fiscal year.

Several equities analysts have recently commented on the stock. Guggenheim assumed coverage on shares of Illumina in a research report on Friday, October 25th. They set a “buy” rating and a $350.00 price target for the company. Cowen set a $320.00 price objective on shares of Illumina and gave the stock a “buy” rating in a report on Friday, October 25th. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Stifel Nicolaus started coverage on shares of Illumina in a research note on Thursday, November 14th. They set a “buy” rating and a $345.00 target price for the company. Finally, ValuEngine upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. Illumina has an average rating of “Buy” and a consensus target price of $333.50.

Several hedge funds have recently added to or reduced their stakes in the business. Next Capital Management LLC bought a new stake in Illumina during the second quarter worth approximately $25,000. Massey Quick Simon & CO. LLC increased its position in shares of Illumina by 3,100.0% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 93 shares during the period. North Star Investment Management Corp. acquired a new position in shares of Illumina during the 3rd quarter valued at $31,000. Trustcore Financial Services LLC bought a new stake in shares of Illumina in the 2nd quarter worth $44,000. Finally, Trust Co. of Vermont raised its stake in shares of Illumina by 296.8% in the 3rd quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock worth $37,000 after buying an additional 92 shares in the last quarter. Institutional investors own 91.77% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: What are municipal bonds?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.